Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone303-703-4906
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Zynex (OTCMKTS:ZYXI) Frequently Asked Questions
What is Zynex's stock symbol?
Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."
How were Zynex's earnings last quarter?
Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings data on Tuesday, October, 29th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.00. The business had revenue of $11.82 million for the quarter, compared to the consensus estimate of $11.06 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.
What price target have analysts set for ZYXI?
2 brokers have issued 1 year price objectives for Zynex's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Zynex's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Price Targets for Zynex.
What is the consensus analysts' recommendation for Zynex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.
Has Zynex been receiving favorable news coverage?
Media coverage about ZYXI stock has trended very negative on Monday, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zynex earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Zynex.
Who are some of Zynex's key competitors?
Some companies that are related to Zynex include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Edap Tms (EDAP), Fonar (FONR), Second Sight Medical Products (EYES), Fc Global Realty (FCRE) and Soleno Therapeutics (SLNO).
What other stocks do shareholders of Zynex own?
Who are Zynex's key executives?
Zynex's management team includes the folowing people:
- Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
- Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
- Mr. David B. Mogill, VP of Operations
- Mr. Robert Bird, VP of Marketing
- Mr. Steve Siefring, Director of Bus. Devel.
Who are Zynex's major shareholders?
Zynex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.84%), Cadence Capital Management LLC (0.76%), Russell Investments Group Ltd. (0.41%), Newman Dignan & Sheerar Inc. (0.10%), Hancock Whitney Corp (0.05%) and Mackay Shields LLC (0.04%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.
Which major investors are selling Zynex stock?
ZYXI stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC and Newman Dignan & Sheerar Inc.. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.
Which major investors are buying Zynex stock?
ZYXI stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Cadence Capital Management LLC, Russell Investments Group Ltd., Hancock Whitney Corp, SRS Capital Advisors Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for Zynex.
How do I buy shares of Zynex?
Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zynex's stock price today?
One share of ZYXI stock can currently be purchased for approximately $9.04.
How big of a company is Zynex?
Zynex has a market capitalization of $296.00 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.
What is Zynex's official website?
How can I contact Zynex?
Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]
MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
